Medtronic

MDT

Market cap $128B

Medtronic is regaining momentum, driven by double-digit growth in key cardiac franchises and a raised full-year revenue outlook. MDT's pulsed-field ablation business surged, with U.S. PFA sales more than tripling, fueling overall cardiovascular strength. Management is shifting to a growth mindset, scaling manufacturing and R&D to capture underpenetrated markets, while maintaining a strong balance sheet.

Enterprise Products Partners will produce significantly more free cash flow in 2026. Medtronic is only two years away from achieving a rare dividend milestone.

Medtronic (MDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors with an interest in Medical - Products stocks have likely encountered both Medtronic (MDT) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two companies is the best option for those looking for undervalued stocks?

Medtronic gains from the FDA clearance of its Hugo RAS system, expanding U.S. access to robotic-assisted urologic surgery.

GALWAY, Ireland , Dec. 4, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 4, 2025, approved the company's cash dividend for the third quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025.

Medtronic recently delivered strong quarterly results thanks to a fast-growing franchise. This tailwind, along with others, could help maintain the stock's momentum into 2026.

Hugo RAS system brings choice to the U.S., coupled with the full suite of Medtronic surgical offerings, ultimately creating a connected and integrated operating room today and into the future. GALWAY, Ireland , Dec. 3, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in surgical innovation, today announced the U.S. Food and Drug Administration (FDA) has cleared the Hugo™ robotic-assisted surgery (RAS) system for use in urologic surgical procedures.

Medtronic begins the U.S. rollout of MiniMed 780G with Abbott's Instinct sensor, advancing diabetes care.

GALWAY, Ireland , Dec. 2, 2025  /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the broad U.S. commercial launch of the MiniMed™ 780G system integrated with the Instinct sensor, made by Abbott and designed exclusively for MiniMed™ systems. Following U.S. FDA clearance of the system earlier this year to enable integration with the Instinct sensor, the system is now shipping to customers across the U.S., marking a major milestone in diabetes technology and delivering a smart, seamless way to manage diabetes.